JP2004517100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517100A5 JP2004517100A5 JP2002551544A JP2002551544A JP2004517100A5 JP 2004517100 A5 JP2004517100 A5 JP 2004517100A5 JP 2002551544 A JP2002551544 A JP 2002551544A JP 2002551544 A JP2002551544 A JP 2002551544A JP 2004517100 A5 JP2004517100 A5 JP 2004517100A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- compound according
- trifluoromethylphenyl
- thiazol
- benzyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 4
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 claims 4
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- SSDUSKOBZBGXRV-UHFFFAOYSA-N 2-methyl-2-[[3-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenyl]methoxy]propanoic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(C)OC1=CC=CC(COC(C)(C)C(O)=O)=C1 SSDUSKOBZBGXRV-UHFFFAOYSA-N 0.000 claims 1
- YPDJBRIAQLVHSE-UHFFFAOYSA-N 2-methyl-2-[[3-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propoxy]phenyl]methoxy]propanoic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(CC)OC1=CC=CC(COC(C)(C)C(O)=O)=C1 YPDJBRIAQLVHSE-UHFFFAOYSA-N 0.000 claims 1
- OQXJAKNLLGBCNA-UHFFFAOYSA-N 2-methyl-2-[[3-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-2-yloxy]phenyl]methoxy]propanoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(C)(C)OC1=CC=CC(COC(C)(C)C(O)=O)=C1 OQXJAKNLLGBCNA-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- UQIJWTDYTYTARD-UHFFFAOYSA-N ethyl 2-methyl-2-[[3-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenyl]methoxy]propanoate Chemical compound CCOC(=O)C(C)(C)OCC1=CC=CC(OC(C)C2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)C)=C1 UQIJWTDYTYTARD-UHFFFAOYSA-N 0.000 claims 1
- YLVIBAKEWWTIEB-UHFFFAOYSA-N ethyl 2-methyl-2-[[3-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-2-yloxy]phenyl]methoxy]propanoate Chemical compound CCOC(=O)C(C)(C)OCC1=CC=CC(OC(C)(C)C2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)C)=C1 YLVIBAKEWWTIEB-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25707000P | 2000-12-20 | 2000-12-20 | |
| PCT/EP2001/014886 WO2002050047A1 (en) | 2000-12-20 | 2001-12-18 | Substitued oxazoles and thiazoles as hppar alpha agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004517100A JP2004517100A (ja) | 2004-06-10 |
| JP2004517100A5 true JP2004517100A5 (https=) | 2005-12-22 |
Family
ID=22974753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002551544A Pending JP2004517100A (ja) | 2000-12-20 | 2001-12-18 | ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7091225B2 (https=) |
| EP (1) | EP1345916A1 (https=) |
| JP (1) | JP2004517100A (https=) |
| AU (1) | AU2002233271A1 (https=) |
| WO (1) | WO2002050047A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| GB0113232D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical process |
| GB0113233D0 (en) | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
| IL160327A0 (en) | 2001-08-13 | 2004-07-25 | Janssen Pharmaceutica Nv | 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
| MXPA04003398A (es) * | 2001-10-12 | 2004-11-22 | Nippon Chemiphar Co | Activador para el receptor o activado con el proliferador de peroxisoma. |
| US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6833380B2 (en) * | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| KR100474202B1 (ko) * | 2002-05-04 | 2005-03-08 | 강헌중 | 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체 |
| EA009554B1 (ru) * | 2002-10-21 | 2008-02-28 | Янссен Фармацевтика Н.В. | Замещённые тетралины и инданы и их применение |
| WO2004037778A1 (en) * | 2002-10-21 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Substituted tetralins and indanes |
| BR0315566A (pt) * | 2002-10-21 | 2005-08-23 | Janssen Pharmaceutica Nv | Tetralinas e indanos substituìdos |
| US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| US6987118B2 (en) * | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
| EP1781265B1 (en) | 2004-08-25 | 2010-04-07 | Essentialis, Inc. | Pharmaceutical formulations of potassium atp channel openers and uses thereof |
| WO2006071103A1 (en) * | 2004-12-31 | 2006-07-06 | Heonjoong Kang | Organoselenium containing compounds and their use |
| CN101146784B (zh) * | 2005-02-25 | 2012-09-05 | 财团法人首尔大学校产学协力财团 | 作为PPARδ配体的噻唑衍生物及其制造方法 |
| EP2404604B1 (en) | 2006-01-05 | 2019-02-06 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
| US9308198B2 (en) | 2006-09-08 | 2016-04-12 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
| EP2170341A4 (en) * | 2007-07-02 | 2010-12-01 | Essentialis Inc | SALTS OF KALIUM ATP CHANNEL OPENERS AND ITS USES |
| US9479586B2 (en) * | 2009-03-05 | 2016-10-25 | Telecom Italia S.P.A. | Distributed system for storing digital data |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| CA2433018A1 (en) * | 2000-12-21 | 2002-06-27 | Joel C. Barrish | Thiazolyl inhibitors of tec family tyrosine kinases |
-
2001
- 2001-12-18 US US10/451,298 patent/US7091225B2/en not_active Expired - Fee Related
- 2001-12-18 JP JP2002551544A patent/JP2004517100A/ja active Pending
- 2001-12-18 EP EP01984857A patent/EP1345916A1/en not_active Ceased
- 2001-12-18 WO PCT/EP2001/014886 patent/WO2002050047A1/en not_active Ceased
- 2001-12-18 AU AU2002233271A patent/AU2002233271A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517100A5 (https=) | ||
| JP2004532266A5 (https=) | ||
| KR100706735B1 (ko) | ｈＰＰＡＲ 알파 활성제로서 치환된 옥사졸 및 티아졸유도체 | |
| JP3490704B2 (ja) | チアゾールおよびオキサゾール誘導体ならびにそれらの医薬的使用 | |
| JP2004518702A5 (https=) | ||
| JP4421895B2 (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
| JP4790969B2 (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
| JP2002522426A (ja) | ｈＰＰＡＲγおよびｈＰＰＡＲαアクチベーターとしての置換オキサゾール類およびチアゾール類誘導体 | |
| JP2004532266A (ja) | 心血管系疾患の治療に有用なチアゾールまたはオキサゾール誘導体 | |
| JP2005529965A5 (https=) | ||
| JP2004534035A5 (https=) | ||
| CN1186489A (zh) | N－苄基二氧代噻唑烷基苯甲酰胺衍生物及其制造方法 | |
| JP2004520377A5 (https=) | ||
| JP2004518702A (ja) | Ｐｐａｒ関連障害治療用のチアゾール誘導体 | |
| JP2007502806A5 (https=) | ||
| JP2005507918A5 (https=) | ||
| WO2002002542A1 (fr) | Compose annulaire a cinq chainons | |
| KR960041168A (ko) | 베타-아드레날린 효능성 작용물질 | |
| JP2004517100A (ja) | ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール | |
| JP2005529965A (ja) | ｈＰＰＡＲ活性化物質としてのフェニルオキシアルカン酸誘導体 | |
| JP2007531764A5 (https=) | ||
| JP2009528997A5 (https=) | ||
| RU2006138494A (ru) | 1, 3, 4-оксадиазол-2-оны в качестве модуляторов ppar-ельта и их применение | |
| JP2004532267A5 (https=) | ||
| KR100859591B1 (ko) | Ｈｐｐａｒ-알파 수용체의 옥사졸/티아졸-유도체 활성제 |